Global Glucagon Like Peptide 1 Analogs Market Is Estimated To Witness High Growth

The global Glucagon Like Peptide 1 Analogs Market is estimated to be valued at US$ 12.55 billion in 2021 and is expected to exhibit a CAGR of 6.10% over the forecast period of 2022 to 2029, according to a new report published by Coherent Market Insights.

 

A) Market Overview:

Glucagon-Like Peptide-1 (Glp-1) Analogs are a class of medications used for the management of type 2 diabetes. They mimic the action of the Glp-1 hormone in the body, which helps regulate blood sugar levels. These drugs are administered through injections and have been proven effective in controlling blood glucose, reducing weight, and decreasing the risk of cardiovascular events. The growing prevalence of diabetes worldwide and the expanding geriatric population are driving the demand for Glp-1 Analogs, resulting in market growth.

 

B) Market Dynamics:

The market dynamics for Glucagon-Like Peptide-1 (Glp-1) Analogs can be attributed to two main drivers. Firstly, the increasing prevalence of diabetes globally is a major driver for market growth. The World Health Organization (WHO) estimates that the number of people with diabetes will reach 552 million by 2030. Glp-1 Analogs provide an effective treatment option for managing diabetes, leading to their high demand in the market.

 

Secondly, the expanding geriatric population is another driver for the Glp-1 Analogs market. The elderly population is more prone to developing diabetes, and with the growing aging population, the demand for diabetes management medications is increasing. Glp-1 Analogs offer a targeted and efficient approach to controlling blood sugar levels in the elderly, making them a preferred choice among healthcare professionals.

 

C) Segment Analysis:

The Glucagon Like Peptide 1 Analogs Market can be segmented based on drug type, distribution channel, and region. By drug type, the market can be divided into Exenatide, Liraglutide, Dulaglutide, and others. Liraglutide is expected to dominate the market due to its high efficacy and preference among healthcare providers. By distribution channel, the market can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are anticipated to be the dominant segment due to the availability of a wide range of Glp-1 Analogs in these settings.

 

D) PEST Analysis:Political: Government initiatives to control the prevalence of diabetes by implementing strict regulations for pharmaceutical companies can impact the growth of the Glp-1 Analogs market.Economic: The increasing healthcare expenditure and the rising affordability of Glp-1 Analogs in developing countries contribute to market growth.Social: Changing lifestyles, unhealthy eating habits, and sedentary lifestyles are major social factors leading to the rise in diabetes cases globally.Technological: Advancements in drug delivery systems and the development of innovative Glp-1 Analogs formulations are driving the market growth.

 

E) Key Takeaways:The global Glucagon Like Peptide 1 Analogs Market is expected to witness high growth, exhibiting a CAGR of 6.10% over the forecast period.The increasing prevalence of diabetes and the expanding geriatric population are the major drivers for market growth.Liraglutide is expected to dominate the market due to its high efficacy and preference among healthcare providers.Hospital pharmacies are anticipated to be the dominant distribution channel for Glp-1 Analogs.Key players operating in the global Glucagon Like Peptide 1 Analogs Market include Sun Pharmaceuticals Industries Ltd, Bristol-Myers Squibb Company, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc, Baxter, Amneal Pharmaceuticals, LLC, Hikma Pharmaceuticals plc, Teva Pharmaceuticals Industries Ltd, Mylan N.V, and Fresenius K.